FDA-Approved Cancer Drugs & Parkinson’s: A New Direction in Research
Synopsis
Researchers identified Aplp1 as a key protein helping toxic alpha-synuclein spread in Parkinson’s disease
The interaction between Aplp1 and LAG-3 appears to drive disease progression
An FDA-approved cancer drug targeting LAG-3 can block this interaction in mouse models
This significantly reduced the spread of harmful proteins, slowing disease progression
The findings suggest a promising strategy: repurposing cancer therapies for neurological diseases
Evaluation
The research offers strong biological insight into how Parkinson’s progresses at a cellular level
Highlights the critical role of protein interactions (Aplp1 + LAG-3) in spreading damage
Demonstrates how existing drugs may be adapted to target entirely different diseases
Research Strategy
Studies were conducted using genetically engineered mouse models
Researchers identified Aplp1 as a surface protein aiding the spread of toxic alpha-synuclein
Earlier studies (2016, 2021) showed LAG-3 binds with alpha-synuclein, enabling its transfer between neurons
However, LAG-3 alone was not sufficient—Aplp1 plays a crucial supporting role Mice lacking Aplp1, LAG-3, or both showed a significant reduction in harmful protein buildup
Injecting LAG-3 antibodies disrupted the Aplp1–LAG-3 interaction
This helped neurons block the uptake and spread of toxic proteins Bottom line: Targeting the partnership between Aplp1 and LAG-3 could open a powerful new pathway to slow or stop Parkinson’s progression—but human trials are still needed. 
For Free Tips Visit: https://tinyurl.com/Parkinsons-Health
Disclaimer: These findings are based on animal studies. Clinical trials in humans are necessary to confirm safety and effectiveness.–
–
–
